Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.

Batbold U, Butov DO, Kutsyna GA, Damdinpurev N, Grinishina EA, Mijiddorj O, Kovolev ME, Baasanjav K, Butova TS, Sandagdorj M, Batbold O, Tseveendorj A, Chunt E, Zaitzeva SI, Stepanenko HL, Makeeva NI, Mospan IV, Pylypchuk VS, Rowe JL, Nyasulu P, Jirathitikal V, Bain AI, Tarakanovskaya MG, Bourinbaiar AS

Open source

DOI: 10.2217/imt-2016-0079
Published: 2017 Jan
Container: Immunotherapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2217/imt-2016-0079,
  title = {Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.},
  author = {Batbold U and Butov DO and Kutsyna GA and Damdinpurev N and Grinishina EA and Mijiddorj O and Kovolev ME and Baasanjav K and Butova TS and Sandagdorj M and Batbold O and Tseveendorj A and Chunt E and Zaitzeva SI and Stepanenko HL and Makeeva NI and Mospan IV and Pylypchuk VS and Rowe JL and Nyasulu P and Jirathitikal V and Bain AI and Tarakanovskaya MG and Bourinbaiar AS},
  year = {2017},
  journal = {Immunotherapy},
  doi = {10.2217/imt-2016-0079},
  url = {https://doi.org/10.2217/imt-2016-0079}
}

RIS

TY  - JOUR
TI  - Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.
AU  - Batbold U
AU  - Butov DO
AU  - Kutsyna GA
AU  - Damdinpurev N
AU  - Grinishina EA
AU  - Mijiddorj O
AU  - Kovolev ME
AU  - Baasanjav K
AU  - Butova TS
AU  - Sandagdorj M
AU  - Batbold O
AU  - Tseveendorj A
AU  - Chunt E
AU  - Zaitzeva SI
AU  - Stepanenko HL
AU  - Makeeva NI
AU  - Mospan IV
AU  - Pylypchuk VS
AU  - Rowe JL
AU  - Nyasulu P
AU  - Jirathitikal V
AU  - Bain AI
AU  - Tarakanovskaya MG
AU  - Bourinbaiar AS
PY  - 2017
JO  - Immunotherapy
DO  - 10.2217/imt-2016-0079
UR  - https://doi.org/10.2217/imt-2016-0079
ER  -

APA

U, B., DO, B., GA, K., N, D., EA, G., O, M., ME, K., K, B., TS, B., M, S., O, B., A, T., E, C., SI, Z., HL, S., NI, M., IV, M., VS, P., JL, R., P, N., V, J., AI, B., MG, T., & AS, B. (2017). Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.. Immunotherapy. https://doi.org/10.2217/imt-2016-0079

Source records

pubmed · retrieved 2026-09-26T10:30:56.696Z